Skip to Main Content
Figure 27-1.

Classification of fungi & pathophysiology of disease.

Table 27-1 Antifungal Drug Susceptibility Rates Against Common Fungal Pathogens (Clin Infect Dis 2009;48:503; J Clin Microbiol 2010;48:3251)


Diagnosis & Evaluation

  • Visualize hyphae after 1 drop of 10–20% KOH added to active lesion border scraping; higher sensitivity (76.5%) & negative predictive value (81.6%) vs culture

Treatment & Follow-Up

  • Tinea capitis: terbinafine 250mg PO daily × 4wk; adjunctive selenium sulfide 2.5% shampoo 2–3×/wk to ↓ spread
  • Tinea corporis, tinea cruris, tinea pedis: combination antifungal/corticosteroid preparations not recommended due to ↑ cost, ↑ risk for adverse effects, & ↓ response rates
  • Tinea unguium (onychomycosis): may withhold treatment for asymptomatic individuals with minimal nail involvement; treat associated tinea pedis in all patients; draw LFTs at baseline & at 4–6wk for terbinafine; for fingernails → terbinafine 250mg PO QD × 6wk (clinical cure rate ∼50%); for toenails →  terbinafine 250mg PO QD × 12wk (clinical cure rate ∼50%) (BMJ 1999; 318:1031); allows 48–72wk for nail growth & to assess clinical cure; in patients with contraindications to systemic therapy (active or chronic liver disease) or minimal distal dermatophyte infection → ciclopirox 8% nail lacquer daily × 48wk + podiatric debridement (mycological cure rate ∼30%; clinical cure rate <10%) (J Am Acad Dermatol 2004;50:151)

| Download (.pdf) | Print
Clinical Pearl 27-1

Topical terbinafine therapy can be applied once daily for 7d for tinea corporis, tinea cruris, & tinea pedis. All other products must be applied for 2–4wk.

| Download (.pdf) | Print
Clinical Pearl 27-2

Clinical cure rates ∼25% in patients >65yo (Am J Geriatr Pharmacother 2006;4:1).

Table 27-2 Topical Antifungal Agents for the Treatment of Tinea Corporis, Tinea Cruris, & Tinea Pedis

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.